novel microfluidics technology that effectively isolates intact and viable CTCs from patients’ blood. The system uses Dean Flow Fractionation for label-free CTC enrichment, capturing heterogeneous and dynamic cancer cells that could be used for cancer screening, diagnosis, staging, personalized medicine and treatment monitoring. Utilizing the next generation non-invasive liquid biopsy to analyze blood samples for CTCs, the device allows for real time analysis of disease before, during, and after treatment, which has become increasingly critical in the new era of precision medicine.


No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *